Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study

BMC Nephrology

Table 5 Muscle composition and size data divided in three groups according to the assigned intervention

Variables	Exercise group	Dopamine agonists group	Placebo group
EMCL CSA (cm ² )
Baseline	13.9±5.1	7.6±2.1	10.0±5.2
6-m post	11.2±5.8	6.8±3.6	9.4±2.0
Δ Change	−2.62±5.15	−0.79±3.33	−0.61±3.92
95% CI of Δ Change	−5.46 to 0.22	−3.86 to 2.21	−4.23 to 3.01
EMCL (%)
Baseline	10.9±3.8	8.7±3.6	8.7±3.9
6-m post	8.2±3.5†	7.1±2.7	8.4±1.5
Δ Change	−2.70±3.90	−1.65±3.45	−0.21±3.54
95% CI of Δ Change	−4.85 to −0.55	−4.83 to 1.53	−3.48 to 3.06
Muscle CSA (cm ² )
Baseline	99.5±14.5	82.5±22.5	98.9±7.3
6-m post	106.8±24.4	89.4±24.5	95.8±2.0
Δ Change	7.32±16.03	6.93±17.66	- 3.15±7.87
95% CI of Δ Change	16.18 to −1.54	23.22 to −9.39	−10.42 to 4.12
Muscle (%)
Baseline	87.9±3.7	85.7±7.2	88.1±3.9
6-m post	88.9±4.5	88.1±5.9	88.2 ±2.2
Δ Change	0.96±5.50	2.39±4.89	0.07±1.64
95% CI of Δ Change	4.00 to −2.04	8.90 to −2.12	1.58 to −1.44
SAT CSA (cm ² )
Baseline	142.8±57.8	88.7±46.7	103.6±28.4
6-m post	143.8±64.8	95.5±39.3	99.7±14.9
Δ Change	0.98±18.88	6.80±19.34	−3.95±17.97
95% CI of Δ Change	11.42 to −9.46	24.67 to −11.07	−20.55 to 12.65

All data are mean ± SD. Abbreviations: EMCL Extramyocellular lipids (fat infiltration), CSA Cross sectional area, SAT Subcutaneous adipose tissue.
†Significantly different from the respective baseline value.